Speman®, A Proprietary Ayurvedic Formulation, Reverses Cyclophosphamide-Induced Oligospermia In Rats

Mohd. Azeemuddin Mukram, Mohamed Rafiq¹, Suryakant D. Anturlikan, Pralhad S. Patki

¹Department of Pharmacology, R&D Center, The Himalaya Drug Company, Makali, Bangalore, India
Abstract

Background: This investigation was aimed to evaluate the effect of Speman®, a well known ayurvedic proprietary preparation, in an experimental model of cyclophosphamide-(CP) induced oligospermia in rats.

Materials and Methods: Thirty male rats were randomized in to five, equally-sized groups. Rats in group 1 served as a normal control; group 2 served as an untreated positive control; groups 3, 4, 5 received Speman® granules at doses of 300, 600, and 900mg/kg body weight p.o. respectively, once daily for 13 days. On day four, one hour after the respective treatment, oligospermia was induced by administering a single dose of CP (100mg/kg body weight p.o.) to all the groups except group1. At the end of the study period the rats were euthanised and accessory reproductive organs were weighed and subjected to histopathological examination. The semen samples were subject to enumeration of sperms. Weight of the reproductive organs, histopathological examination of the tissues, and sperm count were the parameters studied to understand the effect of Speman® on rats with CP-induced oligospermia.

Results: Changes that occurred due to the administration of CP at a dose of 100 mg/kg body weight were dose dependently reversed with Speman® at a dose of 300, 600, and 900 mg/kg body weight. There was a statistically significant increase in sperm count and the weight of the seminal vesicle, epididymis, and prostate.

Conclusion: Findings of this investigation indicate that Speman® dose dependently reversed the CP-induced derangement of various parameters pertaining to the reproductive system. This could explain the total beneficial actions of Speman® reported in several other clinical trials.

Keywords: Speman®, Cyclophosphamide, Oligospermia, Sperm count

Speman®, A Proprietary Ayurvedic Formulation, Reverses Cyclophosphamide-Induced Oligospermia In Rats

Mohd. Azeemuddin Mukram¹, Mohamed Rafiq¹, Suryakant D. Anturlikar¹, Pralhad S. Patki¹

¹Department of Pharmacology, R&D Center, The Himalaya Drug Company, Makali, Bangalore, India

Research

Introduction

Significant growth of the global human population over the years has been paralleled by a substantial increase in the number of infertile couples, a major reproductive-health concern owing to the fact that it affects quality of human life. In human patients, stresses and strains of modern living may make an individual sexually neurasthenic and functionally impotent. This may lead to a chain of psychological complexes, contributing to sexual inferiority and its allied syndromes. Infertility affects both men and women. Current epidemiological evidence suggests that 15% of couples in the world experience infertility, half
of which remain untreated and/or unresolved. Among infertile couples, 40% are primarily due to the infertility of the male partner, while 20% of these cases are a combination of both male and female factors. Oligospermia, asthenospermia, teratozoospermia, and azoospermia account for 20% to 25% of male infertility cases. Clinically, oligospermia (sperm concentrations of < 20 million sperms/mL of semen) is considered to be one of the most prevalent causes of male infertility.

Though the pathophysiology of oligospermia remains unclear, hormones like follicular stimulating hormone (FSH) and luteinizing hormone (LH), which play an important role in spermatogenesis, act as marker components. Treatment options for oligospermia in modern medicine are still in their infancy given that no specific drug has yet been discovered. In the last few years, extensive research has been carried out in the field of Ayurveda for utilizing the natural sources in the treatment of oligospermia.

Speman®, a polyherbal proprietary formulation developed by The Himalaya Drug Company (Makali, Bangalore) is approved by the Government of India’s Drug Regulatory Authority (Department of Ayush, Ministry of Health and Family Welfare). It is used clinically in the management of male sexual disorders like oligospermia, premature ejaculation, senile sex aberrations, and several other related conditions. Several reports are available indicating the beneficial effects of a Speman®, on the gametogenic as well as androgenic functions of the testes in humans and animals.

Speman® constitutes a mixture of extracts of Withania somnifera, Asteracantha longifolia, Lactuca scariola, Mucuna pruriens, Parmelia parlata, Argyreia speciosa, Tribulus terrestris, Leptadenia reticulate, and Suvarnavang. The formulation has been tested for its quality and consistency at every step of the manufacturing process as per the accepted principles of Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP). Its botanical identification, quality parameters, and ayurvedic criteria comply with the international guidelines and pharmacopoeial standards.

Materials and Methods

This investigation was discussed and approved by the Institutional Animal Ethics Committee (IAEC) of The Himalaya Drug Company, Bangalore, on 4/01/2008 vide Protocol No. 83.

Its aim was to evaluate the effect of Speman® in an experimental model of CP-induced oligospermia in rats.

Drugs and chemicals: Speman® (The Himalaya Drug Company, Makali, Bangalore), Cyclophosphamide (CP) (German Remedies Limited, Mumbai, India), and all the other chemicals used in the experiments were of analytical grade and purchased from reputed suppliers.

Experimental animals: Inbred Wistar rats weighing 250–300 g were used for the study; they were housed under standard conditions of temperature (22 ± 3°C), relative humidity (55 ± 5%), and light (12 h light/dark cycle) before and during the study. They were fed with a standard pellet diet and water ad libitum. All animals received humane care as per the guidelines prescribed by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment & Forests, Government of India.

Experimental protocol

Thirty male rats were randomized into five groups of six rats each. Animals from group 1 and 2 received water once a day, orally (p.o.), at a dose of 10 mL/kg body weight; and served as the normal and positive controls, respectively, while those in groups 3 to 5 received Speman® granules at a dose of 300, 600,
and 900 mg/kg body weight p.o. once daily for 13 days. On day four, one hour after their respective treatments, animals in all groups except group 1 received CP at a single dose of 100 mg/kg body weight p.o. Treatment with Speman® was continued for 9 days after administration of CP. At the end of treatment period, on day-14, the animals were euthanized and accessory reproductive organs such as the testes, epididymis, and seminal vesicle were collected, weighed, fixed in neutral buffered formalin solution, and sent for routine histopathological examinations. Semen samples from unilateral cauda were subjected to enumeration of sperms following dilution with sperm diluting fluid. Counting was performed using a haemocytometer and light microscope with 100X magnification.12,13

Results

This preclinical study was carried out to evaluate the effect of Speman® in an experimental model of CP-induced oligospermia in rats. Its efficacy was tested at dose levels of 300, 600, and 900 mg/kg body weight p.o., which corresponds to or equivalent to the recommended human dose. Dosing volume was decided based on the mean body weight of the animals in each group. Administration of CP (100 mg/kg p.o.) to rats induced significant changes, like oligospermia, weight reduction of seminal vesicle, epididymis, and testes.

Sperm count of the normal control group was 46.3 ± 2.89 million/mL of semen and that of the untreated positive control (CP-induced group) was 30.7 ± 1.13 million/mL of semen. The decrease in sperm count observed after administration of CP was reversed dose-dependently by treating with different doses of Speman® (300, 600, and 900 mg/kg). The sperm count was 36.9 ± 1.39, 40.6 ± 0.72, and 42.4 ± 1.07 million/mL in animals from groups 3, 4, and 5, respectively, illustrated in:

Figure 1: Effect of Speman® on sperm count in an experimental model of CP-induced oligospermia in rats.

Increase in sperm count was found to be statistically significant compared to the positive control.

Decrease in weight of seminal vesicles, unilateral epididymis, prostate, and gonads due to the administration of CP was reversed dose-dependently by treating with different doses of Speman®. Increase in weight in all tested doses was found to be statistically significant compared to the positive control group (Figures 2–5, links below).

Figure 2: Effect of Speman® on the absolute weight of seminal vesicle in an experimental model of CP-induced oligospermia in rats.

Figure 3: Effect of Speman® on the absolute weight of unilateral epididymis in an experimental model of CP-induced oligospermia in rats.

Figure 4: Effect of Speman® on absolute weight of prostate in an experimental model of CP-induced oligospermia in rats.

Figure 5: Effect of Speman® on the absolute weight of gonads in an experimental model of CP-induced oligospermia in rats.

The histopathological report (see Table 1) states that treatment with Speman® dose-dependently decreased the mean lesion score of testes, prostate, epididymis, and seminal vesicles.
Table 1: Results of the histopathological evaluation of the accessory reproductive organs following Speman® treatment in rats with CP-induced oligospermia

Discussion

In the present study, CP was used to induce oligospermia in rats. CP is a cytotoxic alkylating agent used in the treatment of neoplasia and autoimmune disorders. Its cytotoxic effects are the result of chemically-reactive metabolites that alkylate DNA and proteins, producing cross-links. It affects rapidly-dividing cells and damages the highly proliferative testis. Thus, the use of this drug for treatment of neoplasia in male patients increases the incidence of oligospermia and azoospermia resulting in male infertility. Animal studies have revealed that treatment of rats/mice with CP leads to transitory oligospermia, decreased testicular weight, DNA synthesis in spermatogonia, protein synthesis in spermatids, and biochemical and histological alterations in the testis and epididymis. The precise mechanism by which CP causes testicular toxicity is unknown. However, numerous studies have shown that exposure to CP can disrupt the redox balance of tissues, suggesting that biochemical and physiological disturbances may result from oxidative stress.

The beneficial effects of Speman® granules in CP-induced oligospermia are due to the synergistic action of the various herbs used in the formulation of Speman®. Most of the herbs present in this formulation have been reported to have a beneficial effect on the male reproductive organs—Mucuna pruriens reduces stress and improves the quality of semen in infertile men; Argyreia nervosa is known for its aphrodisiac property; Asteracantha longifolia and Hygrophila spinosa are reported to improve sexual behavior and reproductive function in male rats; Tribulus terrestris ameliorates the testicular development of immature albino rats.

Conclusion

From the findings reported here, it can be concluded that Speman® is effective in increasing sperm count and weight of sex organs like gonads, seminal vesicles, prostate, and epididymis in rats with CP-induced oligospermia. Treatment with Speman® showed dose-dependent and significant reversal of the CP-induced changes under the testing conditions and doses employed.

Acknowledgement

The authors are thankful to Dr. Gopumadhavan, Toxicology department, R& D Centre, The Himalaya Drug Company for his help in carrying out enumeration of sperms and also acknowledge the work of Dr. Jayashree B Keshav and team (Scientific Publications Division of the Himalaya Drug Company) in terms of editing and proofreading the article.

Conflict of Interest

The formulation of Speman® was received from Formulation Research and Development (F & D) Division, R & D Center, The Himalaya Drug company, Bangalore. No formal funding from any agencies was used for this project, however all the experiments were conducted in Department of Pharmacology, R & D Center, The Himalaya Drug Company, Bangalore. The authors declare no conflict of interest.

References

1. Templeton A. Infertility-epidemiology, aetiology and effective management. Health Bull (Edinb). 1995;53(5):294–298. http://www.ncbi.nlm.nih.gov/pubmed/7490200.
2. Haslett C, Chilvers ER, Boon NA, Colledge NA. Davidson’s principles and practice of medicine. Edinburgh: Churchill Livingstone, 2002:711.
3. Pramanik D. Principles of physiology. Kolkata: Academic Publishers; 2007:370–374.

This work is licensed under a Creative Commons Attribution 3.0 United States License.
4. Agarwal VK, Mittal PC. Clinical studies with Speman in cases of benign enlargement prostate. Probe. 1969; 9:153–156. http://indianmedicine.eldoc.uib.rug.nl/root/A/375

5. Vyas JN, Bhattachariya DD, Bhandari JR. Sexual potency disorders of the male: A clinical trial. Probe. 1970; 9:149–153.

6. Bhatnagar VB. Therapy of the enlarged prostate with Speman. Probe. 1973; 6:29. http://www.himalayahealthcare.com/pdf_files/speman008.pdf

7. Khaleeluddin K, Suresh R, Santpur Rajaram P. Clinical trials in cases of oligozoospermia with Speman. Probe. 1973; XII(4):203. http://www.himalayahealthcare.com/pdf_files/speman038.pdf

8. Kunaiah PP. Role of Speman and Speman forte in oligozoospermia. Probe. 1966; 5:49. http://www.himalayahealthcare.com/pdf_files/confido017.pdf

9. Mukherjee M. Male sterility. Probe. 1973; 4(XII):201–202. http://www.himalayahealthcare.com/pdf_files/speman037.pdf

10. Jadhav SS, Bhaga HS. Effect of Tentex forte and Speman individually and in combination on gonadal structure in rats. J Indian Med Prof. 1971; 18:8055. http://www.himalayahealthcare.com/pdf_files/tforte010.pdf

11. Subbarao VV, Gupta ML, Arora HL. Effect of Speman on the testes – A histological study. Probe. 1966; 4:201–7. http://www.himalayahealthcare.com/pdf_files/tforte011.pdf

12. Das UB, Mallick M, Debnath JM, Ghosh D. Protective effect of ascorbic acid on cyclophosphamide-induced testicular gametogenic and androgenic disorders in male rats. Asian J Androl. 2002; 4:201–7. http://www.ncbi.nlm.nih.gov/pubmed/12364977

13. Matsumoto S, Hirakawa M, Shimomoto T, Sato M, Kitaura K, Minami T. Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats: Effects of a single oral dose of cyclophosphamide. J Toxicol Sci. 2000; 25:139–43. http://www.ncbi.nlm.nih.gov/pubmed/11349437

14. Dollery C. Therapeutic drugs. Edinburgh: Churchill Livingstone; 1999:349–54.

15. Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am. 1998; 27:927–943. http://www.ncbi.nlm.nih.gov/pubmed/9922915

16. Meistrich ML, Parchuri N, Wilson G, Kurdoglu B, Kangasniemi M. Hormonal protection from cyclophosphamide-induced inactivation of rat stem spermatogonia. J Androl. 1995; 16:334–341. http://www.ncbi.nlm.nih.gov/pubmed/8537251

17. Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby PB. Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res. 1995; 330:115–181. http://www.ncbi.nlm.nih.gov/pubmed/7623863

18. Kaur F, Sangha GK, Bilaspuri GS. Cyclophosphamide-induced structural and biochemical changes in testis and epididymis of rats. Indian J Exp Biol. 1997; 35:771–775. http://www.ncbi.nlm.nih.gov/pubmed/9418379

19. Ghosh D, Das UB, Ghosh S, Mallick M, Debnath J. Testicular gametogenic and steroidogenic activities in cyclophosphamide treated rat: A correlative study with testicular oxidative stress. Drug Chem Toxicol. 2002; 25:281–292. http://www.ncbi.nlm.nih.gov/pubmed/12173249

20. Manda K, Bhatia AL. Prophylactic action of melatonin against cyclophosphamide-induced oxidative stress in mice. Cell Biol Toxicol. 2003; 19:367–372. http://www.ncbi.nlm.nih.gov/pubmed/15015761

21. Abraham P, Rabi S. Protective effect of aminoguanidine against cyclophosphamide-induced oxidative stress and renal damage in rats. Redox Rep. 2011; 16(1):8–14. http://www.ncbi.nlm.nih.gov/pubmed/21605493

22. Shukla KK, Mahdi AA, Ahmad MK, Jaiswar SP, Shankwar SN, Tiwari SC. Mucuna pruriens reduces stress and improves the quality of semen in infertile men. eCAM. 2010; 7(1):137–144. http://www.ncbi.nlm.nih.gov/pubmed/18955292

23. Subramoniam A, Madhavachandran V, Ravi K, Anuja VS. Aphrodisiac property of the elephant creeper Argyrea nervosa. J Endocrinol Reprod. 2007; 2(11):82–85. http://srbce.org/jer2007/subramoniametal.pdf

24. Nagendra SC, Vikas S, Dixit VK. Effect of Asteracantha longifolia seeds on the sexual behavior of male rats. Nat Prod Res. 2011; 25(15):1423–1431. http://www.tandfonline.com/doi/abs/10.1080/14786410802588493

25. Sahoo AK, Bhushan G. Effect of Hygrophila spinosa T. on reproductive function of male albino rats. JCIM. 2010; 7(1):1553–3840. http://www.degruyter.com/view/j/jcim.2010.7.1/jcim.2010.7.1.1246.xml

26. Bashir A, Tahir M, Samee W, Munir B. Effects of Tribulus terrestris on testicular development of immature albino rats. Biomed. 2009; 25:63–68. http://www.thebiomedicapk.com/articles/149.pdf

This work is licensed under a Creative Commons Attribution 3.0 United States License.

This journal is published by the University Library System of the University of Pittsburgh as part of its D-Scribe Digital Publishing Program, and is cosponsored by the University of Pittsburgh Press.
Figure 1: Effect of Speman® on sperm count in an experimental model of CP-induced oligospermia in rats.
Figure 2: Effect of Speman® on the absolute weight of seminal vesicle in an experimental model of CP-induced oligospermia in rats.
Figure 3: Effect of Speman® on the absolute weight of unilateral epididymis in an experimental model of CP-induced oligospermia in rats.
Figure 4: Effect of Speman® on absolute weight of prostate in an experimental model of CP-induced oligospermia in rats.
Figure 5: Effect of Speman® on the absolute weight of gonads in an experimental model of CP-induced oligospermia in rats.
Table 1: Results of the histopathological evaluation of the accessory reproductive organs following Speman® treatment in rats with CP-induced oligospermia

| Organs      | Lesions                  | Normal control | Positive control | Speman® (300 mg/kg) | Speman® (600 mg/kg) | Speman® (900 mg/kg) |
|-------------|--------------------------|----------------|------------------|---------------------|---------------------|---------------------|
| Testes      | Interstitial oedema      | 1.67 ± 0.21    | 2 ± 0.63         | 2 ± 0               | 1.5 ± 0.22          | 2.4 ± 0.24          |
|             | Tubular degeneration     | -              | 3.17 ± 0.31      | 3 ± 0               | 1.6 ± 0.25          | 2.2 ± 0.66          |
| Prostate    | Epithelial thinning      | -              | 4 ± 0            | 3 ± 0.52            | 1.8 ± 0.37          | 1.25 ± 0.32         |
| Epididymis  | Epithelial proliferation | -              | 1.83 ± 0.48      | 1.67 ± 0.21         | 1.5 ± 0.22          | 1.0 ± 0             |
| Seminal vesicle | Degeneration         | 2 ± 0.32      | 1.5 ± 0.29       | 2 ± 0.58            | 2 ± 0.52            |                     |

Severity score: Minimal: 1 (very small amount of changes ≤ 10%); Mild: 2 (lesion is easily identified with limited severity 11%–25%); Moderate: 3 (lesion is predominant 26%–75%); Severe: 4 (degree of changes is 76%–100%, that is, great enough in intensity or extent to expect significant tissue or organ dysfunction.)